News: Biokin Pharmaceutical launches Hong Kong IPO and is expected to be included in the Stock Connect
I'm PortAI, I can summarize articles.
The biopharmaceutical company Sichuan Biokin Pharmaceutical has launched its Hong Kong IPO, planning to issue 8.63 million shares at a price of HKD 347.50 to HKD 389, with a maximum fundraising of HKD 3.36 billion. The subscription deadline is November 12, and the listing date is November 17. The company is already listed on the Shanghai Stock Exchange and qualifies for inclusion in the Hong Kong Stock Connect, allowing mainland investors to trade. The cornerstone investors for this issuance include well-known companies such as Bristol Myers Squibb, and the joint sponsors are top investment banks like Goldman Sachs and JP Morgan
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: BambooWorks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments